2. Signaling Pathways
  3. Cytoskeleton
  4. Claudin

Claudin

Claudins are a family of transmembrane proteins, are the most important components of the tight junctions (zonulae occludentes). They have four transmembrane domains, with the N-terminus and the C-terminus in the cytoplasm. Claudin expression and functions are regulated at multiple levels and by diverse mechanisms. Delocalization of claudins from membrane appears to be common among the transformed cells. Constitutive activation of Ras or Ras-mediated signaling pathway/s is one of the initial steps during tumorigenesis that is causatively associated with neoplastic transformation. Importantly, claudins are expressed in the epithelial cells and in a tissue-specific manner and changes among claudin family members in cancer follow tissue-specific and sometimes contrasting pattern. Thus, claudin family of proteins may hold the potential cue to the heterogeneity among the tumors of epithelial origin and beyond being useful markers may also help provide therapeutic opportunities suited for specific cancer type[1].

Claudin Related Products (31):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991140
    Garetatug
    		Ligand 99.48%
    Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity.
    Garetatug
  • HY-P991700
    Lumivatamig
    		Inhibitor
    Lumivatamig is an H-γ1_L-κ-scFvhl dimer-type bispecific antibody targeting CLDN18.2 & CD3E.
    Lumivatamig
  • HY-P991163
    Tixentamig
    		Inhibitor ≥99.0%
    Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers.
    Tixentamig
  • HY-P11785
    Cpe30 MT2
    		Ligand
    Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a Kd value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer.
    Cpe30 MT2
  • HY-P992508
    SPX-101
    		Inhibitor
    SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.
    SPX-101
  • HY-P991946
    Anti-CLDN3 Antibody
    Anti-CLDN3 Antibody is an antibody against human CLDN3. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN3 Antibody
  • HY-P992355
    GB7004-09
    		Inhibitor
    GB7004-09 (GB7004-09hu15) is a humanized monoclonal antibody against CLDN18.2. GB7004-09 can be used in cancer research.
    GB7004-09
  • HY-P992220
    Anti-Claudin 6 Antibody (IM-302)
    Anti-Claudin 6 Antibody (IM-302) is a human monoclonal antibody targeting Claudin-6/CLDN6. Anti-Claudin 6 Antibody (IM-302) can be used in cancer research.
    Anti-Claudin 6 Antibody (IM-302)
  • HY-P992412
    MIL93
    		Inhibitor
    MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001).
    MIL93
  • HY-P992487
    ZL-1211
    		Inhibitor
    ZL-1211 is an anti-CLDN18.2 monoclonal antibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer.
    ZL-1211
  • HY-N2468R
    Xylobiose (Standard)
    		Inhibitor
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome.
    Xylobiose (Standard)